Kornimate/medical-research-clean huggingface dataset:
an open-label, dose-escalation/dose-expansion safety study of incb059872 in subjects with advanced malignancies

Conditions: Solid Tumors and Hematologic Malignancy

Summary: this is an open-label, dose-escalation/dose-expansion study of incb059872 in subjects with advanced malignancies. the study will be conducted in 4 parts. part 1 (mono therapy dose escalation) will determine the recommended dose(s) of incb059872 for dose expansion, based on maximum tolerated dose and/or a tolerated pharmacologically active dose. part 2 (dose expansion) will further determine the safety, tolerability, efficacy, pk, and pd of the selected monotherapy dose(s) in aml/mds, sclc, myelofibrosis, ewing sarcoma, and poorly differentiated neuroendocrine tumors. part 3 will determine the recommended dose(s) of incb059872 in combination with azacitadine and all-trans retinoic acid in aml and in combination with nivolumab in sclc. part 4 will further determine the safety, tolerability, efficacy, pk, and pd of the selected combination dose(s) in part 3.


Eligibility criteria:
inclusion criteria: * male or female subjects, age 18 years or older. * presence of measurable disease that has been confirmed by histology or cytology. * must not be a candidate for potentially curative therapy or standard-of-care approved therapy * eastern cooperative oncology group (ecog) performance status 0 to 2. exclusion criteria: * receipt of anticancer medications, anticancer therapies, or investigational drugs within the defined interval before the first administration of study drug. * any unresolved toxicity ≥ grade 2 from previous anticancer therapy except for stable chronic toxicities (≤ grade 2) not expected to resolve. * laboratory and medical history parameters outside protocol-defined range. * known additional malignancy that is progressing or requires active treatment.

Keywords: acute myeloid leukemia (aml) myelodysplastic syndrome (mds) small cell lung cancer (sclc) myelofibrosis (mf) solid tumor, lysine-specific demethylase 1 (lsd1) inhibitor
quetiapine fumarate (seroquel) in the treatment of adolescent patients with schizophrenia and bipolar i disorder

Conditions: Schizophrenia; Bipolar I Disorder

Summary: the purpose of this study is to demonstrate the efficacy and safety of quetiapine fumarate (seroquel) in the treatment of adolescent patients with schizophrenia and bipolar i disorder.


Eligibility criteria:
inclusion criteria: * patient is able to provide written assent and the parents or legal guardian of the patient are/is able to provide written informed consent before beginning any study related procedures * patient previously enrolled in either double-blind study d1441c00149 or d1441c00112 * patient has documented clinical diagnosis of schizophrenia or bipolar i disorder * patient's parent or legal guardian will be able to accompany the patient to each scheduled study visit exclusion criteria: * patients (female) must not be pregnant or lactating * patients with a known intolerance or lack of response to previous treatment with quetiapine * patients who have previously participated in this study

Keywords: schizophrenia bipolar i disorder
study of varencline effects on cigarette smoking reward and craving during a model of brief quit attempt

Conditions: Nicotine Dependence

Summary: study of varenicline 2.0 mg/day treatment for 2 weeks with smoking test done in laboratory on day 8 and a 1 week quit attempt from day 8-14.


Eligibility criteria:
inclusion criteria: * at least 10 cigarettes/day * interest in quitting smoking * willgness to comply with overnight smoking abbstiennce period followed by lab smoking test exclusion criteria: * pregnancy * axis i psychiatric disorder which require treatment with psychoactive medication and would make study compliance difficult. * clinically significant medical condition in opinion of study clinician * drug or alcohol dependence inlast 12 months * use of other smoking cessation medications ot treatment progams in last 2 months

Keywords: cigarette craving reward
vit d and post-extractive bone turnover

Conditions: Vitamin D Deficiency; Alveolar Bone Loss; Alveolar Bone Resorption

Summary: the aims of the study was to correlate the extent of the dimensional alveolar bone changes after tooth extraction and contextual guided bone regeneration with serum vit d levels in 14 patients. moreover, at 4 months, a small bone sample was collected in order to correlate histological and immunohistochemical parameters of bone with vit d serum levels.

the study included 14 patients requiring tooth extraction and subsequent post-extraction bone regeneration with heterologous graft material of porcine origin. four months after extraction, dental implants were placed, and insertion torque values (itv) and implant stability quotients (isq) were recorded. during implant placement, a small bone sample was collected for histological analysis. the aim of the study was to analyze the correlation between serum vitamin d levels and post-extraction bone volume contraction, collagen type i (col1a1), osteocalcin, osteopontin, runt-related transcription factor 2 (runx2), itv, isq, newly formed bone tissue (nfbt).

Eligibility criteria:
inclusion criteria: * male or female adult (≥ 18 years old) * patients willing to participate and to attend the planned follow-up visits exclusion criteria: * absence of type 1-medical conditions requiring prolonged use of steroids and/or medications that can interfere with bone metabolism * history of leukocyte dysfunction and deficiencies * history of neoplastic disease requiring the use of radiation or chemotherapy * history of renal failure * metabolic disorders such as osteoporosis and correlated vit d or antiresorptive medications assumption * physical handicaps that would interfere with the ability to perform adequate oral hygiene * history of uncontrolled endocrine disorders * alcoholism or any drug abuse * history of immunodeficiency syndromes * smoker of 10 cig per day, cigar equivalents or tobacco chewers * conditions or circumstances which in the opinion of the investigator would prevent completion of study participation or interfere with the analysis of the study results, such as history of non-compliance or unreliability * mucosa disease such as erosive lichen planus * residual post-extraction site with intact bone walls * history of local irradiation therapy * persistent intraoral infection

Keywords: dental implants, alveolar bone loss, alveolar process
evaluation of the accuracy of an implanted glucose sensor

Conditions: Diabetes Mellitus

Summary: the purpose of this clinical investigation is to evaluate the accuracy of the senseonics continuous glucose monitoring system (senseonics cgm system) measurements when compared with reference standard measurements the investigation will also evaluate safety of the senseonics cgm system usage.


Eligibility criteria:
inclusion criteria: 1. adult subjects, age ≥18 years 2. clinically confirmed diagnosis of diabetes mellitus for ≥1 year 3. subject has signed an informed consent form and is willing to comply with protocol requirements exclusion criteria: 1. history of severe hypoglycemia in the previous 6 months. severe hypoglycemia is defined as hypoglycemia resulting in loss of consciousness or seizure 2. history of diabetic ketoacidosis requiring emergency room visit or hospitalization in the previous 6 months 3. female subjects of childbearing capacity (defined as not surgically sterile or not menopausal for ≥ 1 year) who are lactating or pregnant, intending to become pregnant, or not practicing birth control during the course of the study. 4. a condition preventing or complicating the placement, operation, or removal of the sensor or wearing of transmitter, including upper extremity deformities or skin condition. 5. symptomatic coronary artery disease; unstable angina; myocardial infarction, transient ischemic attack or stroke in the past 6 months; uncontrolled hypertension (systolic\>160 mm hg or diastolic \>100 mm hg at time of screening); current congestive heart failure; history of cardiac arrhythmia (benign pacs and pvcs allowed). subjects with asymptomatic coronary artery disease (e,g, cabg, stent placement or angioplasty) may participate if negative stress test within 1 year prior to screening and written clearance from cardiologist documented. 6. hematocrit \ 55% 7. history of hepatitis b, hepatitis c, or hiv 8. any condition that in the investigator's opinion would make the subject unable to complete the study or would make it not in the subject's best interest to participate in the study.

Keywords: type 1 diabetes type 2 diabetes cgm implantable accuracy longevity
primary care clinical practice elements and improving overweight children's weight status

Conditions: Overweight; Childhood Obesity

Summary: the purpose of this study is to identify whether specific clinical practices-including attention to body-mass-index (bmi) screening/overweight/obesity, medical risk (from conditions associated with overweight/obesity such as high blood pressure), and following up to reassess progress-will improve the weight status of overweight school-age children.

the aim of this study is to identify specific clinical practice elements in pediatric primary care that predict improvement in weight status among overweight school-age children. pediatricians are well-suited to regularly assess and treat school-age children who are overweight. well-child visits present an important opportunity to assess and treat overweight children. strategies are needed to maximize the effectiveness of this opportunity. although the american academy of pediatrics endorses recommendations by the united states preventive services task force that clinicians screen for overweight, assess medical/behavior risk, and use a staged treatment approach that includes frequent reassessment, it is unclear whether these practices, when used in primary care, impact whether children make lifestyle changes or improve their weight status. it is essential to identify specific clinical practice elements and communication strategies associated with weight-status improvement in overweight children, to maximize the effectiveness of primary-care weight-management interventions. the investigators hypothesize that, during primary-care visits with overweight 6-12-year-old children, attention to high bmi, medical risk (from weight-related comorbidities such as high blood pressure), and reassessing progress (defined as having a primary-care visit with evidence of attention to bmi or completing a referral to a weight-management specialist or nutritionist) will be associated with improvement in weight status (assessed as decrease in percent overweight (percentage above the age/sex-specific 95th bmi percentile) at follow-up.

Eligibility criteria:
inclusion criteria: * 6-12 year-old children with ≥2 visits * valid height and weight data at each visit * bmi ≥85th percentile at the first visit exclusion criteria: * children \ 12 years old * no valid height and weight data at two visits * bmi \<85th percentile at all 6-12 year-old well child visits

Keywords: childhood obesity childhood overweight primary care weight management
investigating age dependence of fibroblast and extracellular matrix responses to cross-linked hyaluronic acid filler in human skin

Conditions: Photoaging

Summary: the purpose of the study is to investigate the impact of the injection of dermal filler on the quality of the skin dermal extracellular matrix in persons between the ages of 30-50 years. the quality of the dermal extracellular matrix will be assessed following injection of dermal filler compared to injection of saline vehicle.


Eligibility criteria:
inclusion criteria: * subjects must understand and sign the informed consent prior to participation * subjects must be in generally good health * subjects must be able and willing to comply with the requirements of the protocol exclusion criteria: * pregnant, plan to become pregnant during the study, or are nursing a child. participants will be asked to self-report pregnancy * individuals with bleeding disorders * tend to heal poorly or form very thick scars called keloids * have a lidocaine sensitivity, including those with epilepsy, impaired cardiac conduction, severely impaired hepatic function or severe renal dysfunction. * individuals with active inflammation or infection of the skin, including active herpes infection. * have a significant medical history or concurrent condition which the investigator(s) feel is not safe for study participation, including history of frequent herpes infections, and subjects planning to be exposed to excessive sun, ultraviolet lamps and extreme cold weather during the first week after injection. * history of allergies to gram positive bacterial proteins * individuals with who have undergone therapy with thrombolytics, anticoagulants, or inhibitors of platelet aggregation in the preceding 3 weeks. * have an active inflammation or infection of the skin near the site of injection * are taking any medications that suppress your immune system * have severe allergies to medications or other things that we believe might make participation unsafe for you * have a history of connective tissue diseases, such as: * rheumatoid arthritis * scleroderma * polymyositis/dermatomyositis * systemic lupus erythematosus (sle)

Keywords: extracellular matrix hyaluronic acid dermal filler
prevalence and genetic alternation of autoimmune polyglandular syndrome type ii in taiwan

Conditions: Autoimmune Polyendocrine Syndrome Type II

Summary: autoimmune polyendocrine syndrome (aps) is an autoimmune disease involving at least two endocrine organ. it is classified into type i and type ii diseases. among them, aps type ii is more common. it is diagnosed when two of the three following diseases are diagnosed in the same patient, including type 1 diabetes mellitus, autoimmune thyroid disease, and primary adrenal insufficiency. in this study, we will observe the epidemiology, clinical characteristics, and genetic variants of aps ii in taiwan.


Eligibility criteria:
inclusion criteria: * patients visited ntuh during 2006-2021, and had at least two of the three diseases: type 1 dm, primary adrenal insufficiency, and autoimmune thyroid disease. exclusion criteria: * patients aged less than 20 years old
assessment of an school-based intervention in eating habits and physical activity in schoolchildren: the avall study

Conditions: Obesity; Food Habits; Physical Activity

Summary: the objective of the study is to evaluate the efficacy of an intervention on food habits and physical activity in school-age children.

a two-year cluster-randomised prospective study with two parallel arms was used to evaluate an intervention programme in children in their first year of primary schooling (5-6 years of age) in schools in the city of granollers. the intervention consisted of the promotion of healthy eating habits and physical activity by means of the educational methodology investigation, vision, action and change (ivac). at the beginning and at the end of the study (2006 and 2008) the weight and height of each child was measured in situ, while the families were given a self-report physical activity questionnaire and the krece plus quick test.

Eligibility criteria:
inclusion criteria: * children born in 2000 who attended schools in granollers city exclusion criteria: * schoolchildren who need special diet for metabolic or digestive disorder, physical activity incapacity, no family acceptance or attendance to school was discontinued

Keywords: children school-based program obesity
research on the application of electrical impedance tomography in bronchial challenge testing

Conditions: Asthma

Summary: the purpose of this study was to examine whether electrical impedance tomography (eit) was capable of identifying the deteriorated lung function on a regional level during bronchial challenge testing and whether eit may provide additional information during bronchial challenge testing and identify spatial and temporal heterogeneity of regional lung function.

the content of this study includes: 1. can eit identify the uneven ventilation caused by airway contraction in patients during bronchial provocation tests. 2. can eit monitor airway contraction in patients before spirometer examination after inhaling activators. 3. can eit observe uneven ventilation caused by airway contraction through tidal breathing after the patient inhales activator.

Eligibility criteria:
inclusion criteria： 1. patients suspected of asthma who require bronchial challenge testing. 2. the bronchodilator responsiveness testing is negative. 3. patients with a pre-bronchodilator fev1 \>60% predicted. 4. no contraindications for bronchial provocation test examination. 5. fully understand the purpose and significance of this study, and voluntarily participate in the research. exclusion criteria: 1. patients with a pre-bronchodilator fev1≤60% predicted. 1. contraindications for bronchial challenge testing. 2. pregnant or lactating women. 3. after pacemaker surgery.
spinal cord evoked potentials as a tool to investigate sensorimotor processing

Conditions: Studying Spinal Cord Evoked Potentials in Patients With Intractable Pain.

Summary: the study first aim is to investigate the relationship between different patterns of electrode stimulation and peripheral sensory stimulation and spinal cord-evoked potentials to optimize spinal cord stimulation parameters . the second aim of the study is to investigate the role of the spinal cord in some aspects of cognitive-sensory-motor processing, specifically the presence of top-down attentional effects on the sensory analysis of an external stimulus at the spinal cord level. the study will be performed on patients that will be implanted with a spinal epidural electrode because of chronic intractable pain. from these electrodes, spinal cord evoked potentials (sceps) will be recorded.


Eligibility criteria:
inclusion criteria: * age: 18 - 70 * candidates for spinal cord stimulation * epidural electrode at the the level of the cervical or thoracic spine. exclusion criteria: * generalized sensory deficit interfering with the recording of spinal cord evoked potentials
study of uridine triphosphate (utp) as an aerosol spray for cystic fibrosis

Conditions: Cystic Fibrosis

Summary: objectives: i. determine the stability of uridine triphosphate (utp) and examine the metabolism of exogenous nucleotides on airway epithelial surfaces in patients with cystic fibrosis. ii. determine the acute safety and efficacy of aerosolized utp in children with cystic fibrosis.

protocol outline: patients may be treated on any of three different regimens. patients may be treated on more than one regimen, if they meet the eligibility requirements. patients on regimen a are adults and receive uridine triphosphate (utp) by inhalation, followed immediately by bronchoscopy. patients on regimen b are children, aged 4 to 10 years. patients receive up to 4 graded doses of utp by inhalation on day 1. on day 2, patients receive a single dose of utp. patients receive amiloride followed by utp by inhalation on day 3. patients on regimen c are children, aged 4 to 18 years. patients inhale a radiolabelled (technetium 99m) monodisperse iron oxide aerosol. radiation deposited in the patient's lungs is monitored. patients are randomized to receive one of 4 different aerosols (vehicle; utp; amiloride; or utp plus amiloride), which is inhaled for 20 minutes. patients are followed 24 hours after aerosol exposure. regimen d is a dose escalation study in which patients are aged 9 to 40 years. patients receive either the vehicle or utp by inhalation 3 times daily for 3 days. cohorts of 4 patients each are entered at each dose level.

Eligibility criteria:
protocol entry criteria: --disease characteristics-- diagnosis of mild to moderate cystic fibrosis small production of daily airway secretions stable pulmonary course --prior/concurrent therapy-- radiotherapy: no radiation within 12 months to cause patient to exceed annual limits other: no chronic medication for reactive airways disease at least 12 hours since inhaled beta-adrenergic agonists at least 24 hours since systemic theophylline --patient characteristics-- fev1 greater than 50% predicted other: not pregnant must perform reproducible spirometry

Keywords: cardiovascular and respiratory diseases cystic fibrosis genetic diseases and dysmorphic syndromes rare disease
il-6, il-12, il-15 and il-23 expression levels in rheumatoid arthritis patients

Conditions: Rheumatoid Arthritis

Summary: rheumatoid arthritis (ra) is a systemic autoimmune disease characterized by chronic inflammation and articular damage. continuous medical research has dramatically improved the outcomes for patients with ra. traditional therapeutic approaches have relied on glucocorticoids, nonsteroidal anti-inflammatory drugs (nsaids) and disease modifying antirheumatic drugs (dmards) such as methotrexate, sulfasalazine or leflunomide. glucocorticoids and nsaids interfere with the inflammatory cascades while dmards impede both the inflammatory and the destructive processes of ra. these drugs, although efficient, are not specifically directed against inflammatory cells or cytokines and are associated with significant toxicity. the development of biologic dmards (bdmards), has been an important step forward. their ability to neutralize specific cytokines or target distinct immune cells filled a gap in existing treatment options for ra. \[3\]. however, some patients still have only partial or no response to bdmards. more recently, a group of drugs has been developed that inhibit the janus kinase (jak) family of intracellular tyrosine kinases, which transmit cytokine- mediated signals via the jak-signal transducer and activator of transcription (stat) pathway \[4\]. baricitinib, with a selectivity to inhibit jak1 and 2, has been fda approved for ra in 2018 \[5\]. many cytokines such il-6, il-12, il-15, il-23, (gm-csf) and (ifns) are associated with the pathogenesis of ra. these cytokines transduce signals via the jak-stat pathway.


Eligibility criteria:
inclusion criteria: * age is at leasr18 years old, * established ra diagnosis according to 2010 the american college of rheumatology/european league against rheumatism classification criteria exclusion criteria: * associated autoimmune diseases, * connective tissue diseases, * chronic liver or kidney diseases or * genetic diseases
mlpr as a diagnostic marker for acute pulmonary embolism

Conditions: Pulmonary Embolism (Diagnosis); Diagnosis

Summary: a retrospective study to assess the utility of hematological marker (monocyte to large platelet ratio) to diagnose patients with pulmonary embolism

we conducted a retrospective review of emergency department records of patients who presented with signs and symptoms suggestive of pulmonary embolism (pe) and underwent ct pulmonary angiography (ctpa) for diagnosis. hematological laboratory findings obtained prior to any treatment were collected and compared between two groups based on ctpa results: those with confirmed pe (ct positive) and those without pe (ct negative).

Eligibility criteria:
inclusion criteria: * only patients with the results of full blood count and white blood cell differentiation, measured before the treatment of suspected pe. * patients underwent ct pulmonary angiography to confirm or exclude pulmonary embolism diagnosis. exclusion criteria: * patient with his¬tory of any myeloproliferative disorder, myelo¬fibrosis, glanzmann thrombasthenia, may-heg¬glin anomaly, bernard-soulier syndrome, suspicion of disseminated intravascular coagulation. * patient receiving any anticoagulant drug at a therapeutic dose. * patient with blood transfusion in the last 2 months. * patients with acute coronary syndrome, pulmonary edema. * patient on immunosuppressive drugs , oral contraceptive pills . * patients with severe renal or hepatic disease. * patients with stroke. * patients with malignancy.